CLAIMS

1. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide.

2. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide.

3. The peptide of one of the preceding claims, wherein the peptide is SVPFDYNLYSNW; SAPYNFNFYSNW; NIPFNFSLNKER; SVPYQYNWYSNW; SVPWEYNFYSNW; RIPYDRGMIVNV; KVPYDWDSVINL; QLPYDVHTYNDW; LAPYDHNRYTQW; SNPYDLEAYENW; SVPYDYQGYRNI; SVPYDYNVYLNK; IQPYDKNYFQNF; VVPYDINIKDNW; SVPYDYNPYSNW; SVPYDYNKLKNW; SVPYDYNWRSSW; SVPYDYNWWSAW; SVPYDYNWQSNW; ELSSFNFDWYNV; RYSSFDYDWYNV; NVHSFDYDWYNV; RVESFNYDWYNV; RVESFDFDWYNI; RINSFDYDWYNV; TVNSFDYDWYNV; KVNSFDYDWYNV; TVHSFDYDWYNV; SVHSWDYDWYNV; SVHSYDFDWYNV; TLQAFNYEWYQL; KYETFEYGWYNI; HGDSFQYEWYNL; SVHSFDWDWYNV; SVHSFDYDYYNV; SVHSFDYDFYNV; SVHSFDYDWFNV; SVHSFDYDWWNV; IFNPFDYDWYNV; QWHSFDYDWYNV or DVHPFDYDWYNV, and wherein said peptide is a cyclic peptide.

~~4. The peptide of one of the preceding claims, wherein said peptide is cyclic peptide.~~

~~5~~4. The peptide of one of the preceding claims, wherein said peptide is soluble.

~~6~~5. The peptide of one of the preceding claims, wherein said peptide is attached to a linker.

~~7~~6. The peptide of claim ~~6~~ 5, wherein said linker is polyethylene glycol or palmitic acid.

~~8~~7. The peptide of one of the preceding claims, wherein the peptide is synthetic.

~~9~~8. A composition comprising a protein or peptide according to any one of the preceding claims, wherein said composition is capable of detaching a single cell organism from a surface or from other single cell organisms.

~~10~~9. The composition of claim ~~9~~ 8, wherein said protein or peptide is from a human or aquatic organism.

~~11~~10. The composition of claim ~~9~~ 8, wherein said peptide consists of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW.

~~12~~11. The composition of claim ~~9~~ 8, wherein said peptide consists of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV.

~~13~~12. The composition of claim ~~11~~10 or ~~12~~ 11, wherein the peptide is SVPFDYNLYSNW; SAPYNFNFYSNW; NIPFNFSLNKER; SVPYQYNWYSNW;

SVPWEYNFYSNW; RIPYDRGMIVNV; KVPYDWDSVINL; QLPYDVHTYNDW; LAPYDHNRYTQW; SNPYDLEAYENW; SVPYDYQGYRNI; SVPYDYNVYLNK; IQPYDKNYFQNF; VVPYDINIKDNW; SVPYDYNPYSNW; SVPYDYNKLKNW; SVPYDYNWRSSW; SVPYDYNWWSAW; SVPYDYNWQSNW; ELSSFNFDWYNV; RYSSFDYDWYNV; NVHSFDYDWYNV; RVESFNYDWYNV; RVESFDFDWYNI; RINSFDYDWYNV; TVNSFDYDWYNV; KVNSFDYDWYNV; TVHSFDYDWYNV; SVHSWDYDWYNV; SVHSYDFDWYNV; TLQAFNYEWYQL; KYETFEYGWYNI; HGDSFQYEWYNL; SVHSFDWDWYNV; SVHSFDYDYYNV; SVHSFDYDFYNV; SVHSFDYDWFNV; SVHSFDYDWWNV; IFNPFDYDWYNV; QWHSFDYDWYNV or DVHPFDYDWYNV, and wherein said peptide is a cyclic peptide.

~~14. The composition of one of claims 9-13, wherein said peptide is a cyclic peptide.~~

~~15~~13. The composition of one of claims ~~9-14~~ 8-12, wherein said peptide is soluble.

~~16~~14. The composition of one of claims ~~9-15~~ 8-13, wherein said peptide is attached to a linker.

~~17~~15. The composition of claim ~~16~~ 14, wherein said linker is polyethylene glycol or palmitic acid.

~~18~~16. The composition of one of claims ~~9-17~~ 8-15, wherein the peptide is synthetic.

~~19~~17. The composition of one of claims ~~9-18~~ 8-16, wherein said organism is in a biofilm.

~~20~~18. The composition of one of claims ~~9-19~~ 8-17, wherein said organism is an aquatic organism.

~~21~~19. The composition of one of claims ~~9-20~~ 8-18, wherein said organisms are attached in a cluster or aggregate.

~~22~~20. The composition of one of claims ~~9-21~~ 8-19, wherein said composition is capable of breaking or dispersing said cluster or aggregate.

~~23~~21. The composition of one of claims ~~9-22~~ 8-20, wherein said detaching affects the ability of said organism to produce polysaccharide matrix.

~~24~~22. The composition of one of claims ~~9-23~~ 8-21, wherein said surface is a selected from the group comprising a fabric, a fiber, a foam, a film, a concrete, a masonry, a glass, a metal and a plastic.

~~25. A method of detaching a single cell organism from a surface or from other single cell organisms, comprising contacting said organism with a composition comprising a protein or peptide.~~

~~26. The method of claim 25, wherein said protein or peptide is from a human or aquatic organism.~~

~~27~~23. The method of ~~claim 25~~of detaching a single cell organism from a surface or from other single cell organisms, comprising contacting said organism with a composition comprising a protein or peptide, wherein said peptide consists of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW , and wherein said peptide is a cyclic peptide.

~~28~~24. The method of ~~claim 25~~ of detaching a single cell organism from a surface or from other single cell organisms, comprising contacting said organism with a composition comprising a protein or peptide, wherein said peptide consists of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W;

X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide.

~~29~~25. The method of one of claims ~~27-28~~ 23-24, wherein the peptide is SVPFDYNLYSNW; SAPYNFNFYSNW; NIPFNFSLNKER; SVPYQYNWYSNW; SVPWEYNFYSNW; RIPYDRGMIVNV; KVPYDWDSVINL; QLPYDVHTYNDW; LAPYDHNRYTQW; SNPYDLEAYENW; SVPYDYQGYRNI; SVPYDYNVYLNK; IQPYDKNYFQNF; VVPYDINIKDNW; SVPYDYNPYSNW; SVPYDYNKLKNW; SVPYDYNWRSSW; SVPYDYNWWSAW; SVPYDYNWQSNW; ELSSFNFDWYNV; RYSSFDYDWYNV; NVHSFDYDWYNV; RVESFNYDWYNV; RVESFDFDWYNI; RINSFDYDWYNV; TVNSFDYDWYNV; KVNSFDYDWYNV; TVHSFDYDWYNV; SVHSWDYDWYNV; SVHSYDFDWYNV; TLQAFNYEWYQL; KYETFEYGWYNI; HGDSFQYEWYNL; SVHSFDWDWYNV; SVHSFDYDYYNV; SVHSFDYDFYNV; SVHSFDYDWFNV; SVHSFDYDWWNV; IFNPFDYDWYNV; QWHSFDYDWYNV or DVHPFDYDWYNV , and wherein said peptide is a cyclic peptide.

~~30. The method of one of claims 25-29, wherein said peptide is a cyclic peptide.~~

~~31~~26. The method of one of claims ~~25-30~~ 23-25, wherein said peptide is soluble.

~~32~~27. The method of one of claims ~~25-31~~ 23-26, wherein said peptide is attached to a linker.

~~33~~28. The method of claim ~~32~~ 27, wherein said linker is polyethylene glycol or palmitic acid.

~~34~~29. The method of one of claims ~~25-33~~ 23-28, wherein the peptide is synthetic.

~~35~~30. The method of one of claims ~~25-34~~ 23-29, wherein said surface is selected from the group comprising a fabric, a fiber, a foam, a film, a concrete, a masonry, a glass, a metal and a plastic.

~~36~~31. The method of one of claims ~~25-35~~ 23-30, wherein said organism is in a biofilm.

~~37~~32. The method of one of claims ~~25-36~~ 23-31, wherein said organism is an aquatic organism.

~~38~~33. The method of one of claims ~~25-37~~ 23-32, wherein said organisms are attached in a cluster or aggregate.

~~39~~34. The method of one of claims ~~25-38~~ 23-33, wherein said composition breaks or disperses said cluster or aggregate.

~~40~~35. The method of one of claims ~~25-39~~ 23-34, wherein said composition prevents said organism from producing polysaccharide matrix.

~~41~~36. The method of one of claims ~~25-40~~ 23-35, wherein said surface is a selected from the group comprising a fabric, a fiber, a foam, a film, a concrete, a masonry, a glass, a metal and a plastic.

~~42~~37. A pharmaceutical composition comprising the composition of one of claims ~~9-24~~8-22 and a pharmaceutically acceptable carrier or diluent.

~~43~~38. The pharmaceutical composition according to claim ~~42~~ 37 for use in a method of preventing or treating a pathogen infection in a subject in need thereof, wherein the pharmaceutical composition of claim ~~42~~37 is for administering to the subject in a therapeutically effective amount.

~~44~~39. The composition of one of claims ~~9-24~~8-22 for use in a method of increasing the effectiveness of a pharmaceutical composition, wherein the composition of one of claims 9-24 is for administering to a subject in need of the pharmaceutical composition.

~~45~~40. The composition for the use of claim ~~44~~ 39, wherein said pharmaceutical composition is an antibiotic.

~~46~~41. A method of identifying an anti-biofilm composition, the method comprising

(a) contacting said biofilm with a plurality of compositions, each composition comprising a protein or peptide;

(b) assaying the ability of said biofilm to resist anti-bioflim activity, wherein said anti-bioflim activity comprises detaching said biofilm from a surface or breaking up said biofilm; and

(c) identifying from said plurality of compositions at least one composition having said anti-biofilm activity above a predetermined threshold, thereby identifying the anti-biofilm composition.

~~47~~42. The method of claim ~~46~~ 41, wherein the peptide is SVPFDYNLYSNW; SAPYNFNFYSNW; NIPFNFSLNKER; SVPYQYNWYSNW; SVPWEYNFYSNW; RIPYDRGMIVNV; KVPYDWDSVINL; QLPYDVHTYNDW; LAPYDHNRYTQW; SNPYDLEAYENW; SVPYDYQGYRNI; SVPYDYNVYLNK; IQPYDKNYFQNF; VVPYDINIKDNW; SVPYDYNPYSNW; SVPYDYNKLKNW; SVPYDYNWRSSW; SVPYDYNWWSAW; SVPYDYNWQSNW; ELSSFNFDWYNV; RYSSFDYDWYNV; NVHSFDYDWYNV; RVESFNYDWYNV; RVESFDFDWYNI; RINSFDYDWYNV; TVNSFDYDWYNV; KVNSFDYDWYNV; TVHSFDYDWYNV; SVHSWDYDWYNV; SVHSYDFDWYNV; TLQAFNYEWYQL; KYETFEYGWYNI; HGDSFQYEWYNL; SVHSFDWDWYNV; SVHSFDYDYYNV; SVHSFDYDFYNV; SVHSFDYDWFNV; SVHSFDYDWWNV; IFNPFDYDWYNV; QWHSFDYDWYNV or DVHPFDYDWYNV, and wherein said peptide is a cyclic peptide.

~~48~~43. A medical device comprising the composition of one of claims ~~9-24~~ 8-22.

~~49~~44. A method of dispersing a biofilm or detaching biofilm formation from a surface, the method comprising treating water with or coating said surface with the composition of one of claims ~~9-24~~ 8-22.

~~50~~45. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K,

F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide,for use in a method of treating a disease, wherein said peptide is for administering to a subject.

~~51~~46. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide, for use in a method of treating a disease, wherein said peptide is for administering to a subject.

~~52~~47. The peptide for the use of one of claims ~~50-51~~ 45-46, wherein the disease is autoimmune, inflammatory or degenerative disease.

~~53~~48. The peptide for the use of claim ~~52~~ 47, wherein the disease is Alzheimer's Disease.

~~54~~49. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide,for use in a method of reducing restenosis, wherein said peptide is for administering to a subject.

~~55~~50. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide,for use in a method of reducing restenosis, wherein said peptide is for administering to a subject.

~~56~~51. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide, for use in a method of reducing white blood cell clustering, wherein said peptide is for administering to a subject.

~~57~~52. A peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide,for use in a method of reducing white blood cell clustering, wherein said peptide is for administering to a subject.

~~58~~53**.** Use of a therapeutically effective amount of the composition of one of claims ~~9-24~~8-22 in the preparation of a medicament for preventing or treating a pathogen infection in a subject.

~~59~~54. Use of the composition of one of claims ~~9-24~~8-22 in the preparation of a medicament for administering to a subject in need of a pharmaceutical composition to enhance the effectiveness of said pharmaceutical composition.

~~60~~55. Use according to claim ~~59~~ 54, wherein the pharmaceutical composition is an antibiotic.

~~61~~56. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R,

V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide,for the preparation of a medicament for ~~for~~ treating a disease.

~~62~~57. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide,for the preparation of a medicament for treating a disease.

~~63~~58. Use according to one of claims ~~61-62~~ 56-57, wherein the disease is autoimmune, inflammatory or degenerative disease.

~~64~~59. Use according to claim ~~63~~ 58, wherein the disease is Alzheimer's Disease.

~~65~~60. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide, for the preparation of a medicament for reducing restenosis.

~~66~~61. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, I, V, R, K, Q or L; X^2 is V, I, A, N, L or Q; X^3 is P; X^4 is Y, F or W; X^5 is D, N, Q or E; X^6 is Y, F , R, W, V, H, L, K or I; X^7 is N, S, G, D, H, E, Q or I; X^8 is W, L, F, M S, T, R, A, G, V, P, Y, I or K; X^9 is Y, N, F, K, L, R, I, V, W or Q; X^{10} is S, K, N, T, E, R, L, Q, I ,V, D, or K; X^{11} is N, E, D, Q, S, A or I; and X^{12} is W, R, V, L, I, K, F or E, wherein the peptide is not SVPYDYNWYSNW, and wherein said peptide is a cyclic peptide, for the preparation of a medicament for reducing white blood cell clustering.

~~67~~62. Use of a peptide consisting of amino acids X^1-X^2-X^3-X^4-X^5-X^6-X^7-X^8-X^9-X^{10}-X^{11}-X^{12}, wherein X^1 is S, N, T, K, R, H, E, I, Q or D; X^2 is V, I, L, Y, G, F or W; X^3 is H, N, Q, E, D or S; X^4 is S, P, A or T; X^5 is F, W or Y; X^6 is D, N, E or Q; X^7 is Y, F or W; X^8 is D, G or E; X^9 is W, F or Y; X^{10} is Y, F or W; X^{11} is N or Q; and X^{12} is V, I or L, wherein the peptide is not SVHSFDYDWYNV, and wherein said peptide is a cyclic peptide, for preparation of a medicament for reducing white blood cell clustering.